Paediatric Respiratory Reviews
Volume 7, Issue 1 , Pages 54-59 , March 2006

The relationship between paediatricians and commerce

  • Tom Hilliard

      Affiliations

    • Department of Respiratory Paediatrics, Great Ormond Street Hospital, London WC1N 2JH, UK
    • ,
  • Timothy Chambers

      Affiliations

    • Department of Paediatrics, Southmead Hospital, Bristol BS10 5NB, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 117 959 5327; fax: +44 117 959 5382.

References 

  1. Ferner RE. The influence of big pharma. BMJ. 2005;330:855–856
  2. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians’ relationships with the pharmaceutical industry—self-regulation in the shadow of federal prosecution. N Engl J Med. 2004;351:1891–1900
  3. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885–1890
  4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185
  5. House of Commons Health Committee. The influence of the pharmaceutical industry. http://www.parliament.the-stationery-office.co.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf.
  6. Scherer FM. The pharmaceutical industry–prices and progress. N Engl J Med. 2004;351:927–932
  7. General Medical Council. Good Medical Practice. Duties and responsibilities of doctors. http://www.gmc-uk.org/standards/GMP.pdf.
  8. Royal College of Paediatrics and Child Health. Good Medical Practice in Paediatrics and Child Health. Duties and responsibilities of paediatricians. http://www.rcpch.ac.uk/publications/recent_publications/GMP.pdf.
  9. Royal College of Physicians. The relationship between physicians and the biomedical industries: advice of the Royal College of Physicians. http://www.rcplondon.ac.uk/college/statements/advice_biomedIndustry.htm.
  10. Association of the British Pharmaceutical Industry. ABPI code of practice for the pharmaceutical industry. http://www.abpi.org.uk
  11. Pharmaceutical Research and Manufacturers of America. Code on interactions with healthcare professionals. http://www.phrma.org/publications/policy/2004-01-19.391.pdf.
  12. American Medical Association. Opinion of the Council on Ethical and Judicial Affairs, E-8.061. http://www.ama-assn.org/ama/pub/category/4001.html.
  13. Coyle SL. Physician–industry relations. Part 1: individual physicians. Ann Intern Med. 2002;136:396–402
  14. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med. 2003;163:2213–2218
  15. Gibbons RV, Landry FJ, Blouch DL, et al. A Comparison of Physicians’ and Patients’ Attitudes Toward Pharmaceutical Industry Gifts. Journal of General Internal Medicine. 1998;13:151–154
  16. Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ. 1995;153:553–559
  17. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?. JAMA. 2000;283:373–380
  18. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8:13–20
  19. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest. 1992;102:270–273
  20. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001;110:551–557
  21. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290:252–255
  22. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth. 2003;3:39–46
  23. Watkins RS, Kimberly J. What residents don’t know about physician–pharmaceutical industry interactions. Acad Med. 2004;79:432–437
  24. Hopper JA, Speece MW, Musial JL. Effects of an educational intervention on residents’ knowledge and attitudes toward interactions with pharmaceutical representatives. J Gen Intern Med. 1997;12:639–642
  25. Agrawal S, Saluja I, Kaczorowski J. A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. Acad Med. 2004;79:1046–1050
  26. Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN. The ethics of pharmaceutical industry relationships with medical students. Med J Aust. 2004;180:411–414
  27. Wofford JL, Ohl CA. Teaching appropriate interactions with pharmaceutical company representatives: the impact of an innovative workshop on student attitudes. BMC Med Educ. 2005;5:5
  28. Relman AS. Separating continuing medical education from pharmaceutical marketing. JAMA. 2001;285:2009–2012
  29. Holmer AF. Industry strongly supports continuing medical education. JAMA. 2001;285:2012–2014
  30. The Royal Australasian College of Physicians. Ethical guidelines in the relationship between physicians and the pharmaceutical industry. http://www.racp.edu.au/public/Ethical_guide_pharm.pdf.
  31. Moses H, Martin JB. Academic relationships with industry: a new model for biomedical research. JAMA. 2001;285:933–935
  32. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454–465
  33. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomised controlled drug trials. Fam Pract. 2001;18:565–568
  34. Ashar BH, Miller RG, Getz KJ, Powe NR. Prevalence and determinants of physician participation in conducting pharmaceutical-sponsored clinical trials and lectures. J Gen Intern Med. 2004;19:1140–1145
  35. Glaxo faces drug fraud lawsuit. Guardian. 3.6.2004.
  36. Association of the British Pharmaceutical Industry. Clinical trial agreement for pharmaceutical industry sponsored research in NHS trusts. www.abpi.org.uk/publications/pdfs/Model_Clinical_Trial_Agreement_Final.pdf.
  37. Clinical Trials Directive (2001/20/EC). http://medicines.mhra.gov.uk/ourwork/licensingmeds/types/clintrialdir.htm.
  38. EudraCT. European Clinical Trials Database. http://eudract.emea.eu.int/.
  39. Conroy S, Choonara I, Impiccatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ. 2000;320:79–82
  40. Steinbrook R. Testing medications in children. N Engl J Med. 2002;347:1462–1470
  41. Medicines for Children – The European Paediatric Initiative. http://www.emea.eu.int/htms/human/peg/pegfaq.htm.
  42. Lucas A. Should industry sponsor research? Collaborative research with infant formula companies should not always be censored. BMJ. 1998;317:337–338
  43. Waterston T, Nathwani A, Morley D, et al. Should industry sponsor research? Researchers must recognise damage done by overt association with formula manufacturers. BMJ. 1999;318:260
  44. Stelfox HT, Chua G, O’Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338:101–106
  45. Smith R. Beyond conflict of interest. Transparency is the key. BMJ. 1998;317:291–292
  46. Drazen JM, Curfman GD. Financial associations of authors. N Engl J Med. 2002;346:1901–1902
  47. Task force on financial conflicts of interest in clinical research. Protecting subjects, preserving trust, promoting progress: policy and guidelines for the oversight of individual financial interests in human subjects research. Washington, D.C., American Association of Medical Colleges. http://www.aamc.org/members/coitf/firstreport.pdf.
  48. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287:612–617
  49. Chambers TL. The relationship between European paediatricians and commerce: ethical principles in paediatrics working group recommendations. Confederation of European Societies of Paediatrics (CESP). Eur J Pediatr. 2000;159:116–118
  50. Royal College of Paediatrics and Child Health. Commercial sponsorship in the Royal College of Paediatrics and Child Health. Report of a working party. 2001.
  51. Herxheimer A. Relationships between the pharmaceutical industry and patients’ organisations. BMJ. 2003;326:1208–1210
  52. Smith R. Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ. 2003;326:1202–1205
  53. Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med. 2005;352:325–328
  54. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. BMJ. 2003;326:1193–1196
  55. No Free Lunch. http://www.nofreelunch.org/.
  56. PharmFree. American Medical Student Association. http://www.amsa.org/prof/pharmfree.cfm.
  57. Healthy Skepticism. http://healthyskepticism.org/.

PII: S1526-0542(05)00086-2

doi: 10.1016/j.prrv.2005.09.004

Paediatric Respiratory Reviews
Volume 7, Issue 1 , Pages 54-59 , March 2006

Article Tools